Literature DB >> 27778443

Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch.

Marcin Krawczyk1,2, Roman Liebe2, Michał Wasilewicz3, Ewa Wunsch4, Joanna Raszeja-Wyszomirska3, Piotr Milkiewicz3,4.   

Abstract

BACKGROUND & AIMS: The amelioration of refractory cholestatic pruritus after plasmapheresis has been reported in single patients. Here, we analyse the efficacy of plasmapheresis in a cohort of patients with primary biliary cholangitis (PBC).
METHODS: Seventeen consecutive patients with PBC (age range 39-85 years, 16 females, 9 with cirrhosis) and refractory pruritus underwent 129 plasmapheresis procedures during 40 admissions. Pruritus was quantified by the 10-point numeric rating scale (NRS) before and after plasmapheresis, as well as ~30 and ~90 days later.
RESULTS: The mean pruritus before plasmapheresis did not differ between patients with and without cirrhosis (P>.05). Cirrhotics presented, however, with significantly higher serum alanine aminotransferase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and bilirubin before plasmapheresis. Plasmapheresis decreased itching to NRS≤5 in all but five admissions: Mean pruritus decreased from 8.3±1.4 to 3.1±2.2 (P<.0001) in the entire cohort. It also led to a significant decrease in serum ALT, ALP, AST, GGT (all P<.001) and bilirubin (P=.002). Antipruritic effect persisted throughout the 90-days follow-up (P<.0001). The amelioration of pruritus was not affected by the presence of cirrhosis.
CONCLUSIONS: Plasmapheresis is a promising method for reducing intractable itch in a significant proportion of PBC patients regardless of liver fibrosis. Long-lasting improvement of symptoms requires repeated procedures.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Cholestasis; cirrhosis; itch; rifampicin

Mesh:

Substances:

Year:  2016        PMID: 27778443     DOI: 10.1111/liv.13281

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

1.  Extracorporeal devices for treatment of refractory pruritus in cholestatic liver disease.

Authors:  Roger Williams
Journal:  Hepatol Int       Date:  2017-06-06       Impact factor: 6.047

2.  Cholestatic pruritus: Emerging mechanisms and therapeutics.

Authors:  Sagar P Patel; Chirag Vasavda; Byron Ho; James Meixiong; Xinzhong Dong; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2019-04-19       Impact factor: 11.527

Review 3.  Novel strategies and therapeutic options for the management of primary biliary cholangitis.

Authors:  Amardeep Khanna; David E Jones
Journal:  Therap Adv Gastroenterol       Date:  2017-09-07       Impact factor: 4.409

4.  Can genetic testing guide the therapy of cholestatic pruritus? A case of benign recurrent intrahepatic cholestasis type 2 with severe nasobiliary drainage-refractory itch.

Authors:  Robert Holz; Andreas E Kremer; Dieter Lütjohann; Hermann E Wasmuth; Frank Lammert; Marcin Krawczyk
Journal:  Hepatol Commun       Date:  2018-01-10

Review 5.  Cholestasis-Associated Pruritus and Its Pruritogens.

Authors:  Jacqueline A G M Langedijk; Ulrich H Beuers; Ronald P J Oude Elferink
Journal:  Front Med (Lausanne)       Date:  2021-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.